Should I perform a gradual dose reduction (GDR) of psychotropic medications for hospice patients?

Gradual Dose Reduction (GDR) of Psychotropic Medications in Hospice Patients

You should generally NOT perform gradual dose reduction of psychotropic medications in hospice patients; instead, focus on deprescribing medications that are no longer aligned with comfort-focused goals while continuing or even initiating psychotropics when needed for symptom management of delirium, agitation, or distress.

Core Principle: Align Medications with Comfort Goals

The fundamental approach in hospice is to continue medications that provide symptom palliation and discontinue those that are ineffective, cause distressing side effects, or are inconsistent with comfort-focused care 1. This is distinctly different from traditional GDR protocols used in other settings.

When to Continue or Initiate Psychotropics

Antipsychotics and Benzodiazepines Should Be Maintained or Started When:

• Delirium is present with perceptual disturbances (hallucinations, illusions) 1
• Severe agitation poses risk to the patient or others 1
• Refractory symptoms at end of life require palliative sedation 1

Key caveat: Antipsychotics and benzodiazepines themselves can cause or worsen delirium and agitation, so they should be used at the lowest effective doses 1. However, this does not mean tapering existing therapeutic doses—it means starting low if initiating new therapy.

Medications to Actually Deprescribe in Hospice

The evidence strongly supports deprescribing medications aimed at primary prevention or long-term disease management, not psychotropics used for symptom control 2, 3, 4:

High-Priority Medications for Deprescribing:

• Statins (median discontinuation time: 93 days in hospice—far too long) 3
• Diabetes medications (median discontinuation: 197 days) 3
• Proton pump inhibitors (often continued unnecessarily throughout hospice stay) 3
• Cardiovascular medications for primary prevention 2

A pharmacist-led deprescribing program achieved 79.4% success in reducing ≥50% of inappropriate medications in hospice patients, with more frequent encounters associated with 3.2-fold higher odds of success 2.

The Critical Distinction: Symptom Management vs. Disease Prevention

Psychotropic medications in hospice serve an active symptom management role, not a preventive one 1. The 2018 ESMO guidelines explicitly state that medications for symptom palliation used before sedation should be continued unless they are ineffective or have distressing side effects 1.

Specific Guidance on Continuing Psychotropics:

• Patients on antipsychotics for delirium management should continue them at effective doses 1
• Benzodiazepines for anxiety or terminal agitation should be maintained 1
• Dose adjustments should be made for efficacy or adverse effects, not according to arbitrary tapering schedules 1

When Dose Reduction IS Appropriate

The only scenario where reducing psychotropic doses makes sense in hospice:

• Signs of overdose or adverse effects (e.g., respiratory suppression with benzodiazepines, excessive sedation, paradoxical agitation) 1
• Withdrawal risk: If doses must be reduced after continuous infusion, do so gradually to avoid withdrawal symptoms 1

Important: Even when opioid overdose signs appear, doses should be reduced but not discontinued entirely 1.

Common Pitfalls to Avoid

1. Applying non-hospice GDR protocols: The hyperbolic tapering strategies described for psychiatric drug discontinuation 5, 6 are designed for patients with longer life expectancies and different goals of care—they are inappropriate in hospice settings.

2. Confusing polypharmacy reduction with psychotropic tapering: Deprescribing efforts should target preventive medications, not symptom management drugs 2, 3, 4.

3. Premature discontinuation: Medications like haloperidol, olanzapine, or lorazepam that control distressing symptoms should not be tapered simply because the patient is in hospice 1.

Practical Algorithm

For each psychotropic medication, ask:

1. Is it managing a current symptom (delirium, agitation, anxiety, distress)?

   • YES → Continue at effective dose 1
   • NO → Consider deprescribing 4

2. Are there adverse effects or signs of overdose?

   • YES → Reduce dose cautiously, do not abruptly stop 1
   • NO → Maintain current dose 1

3. Is the patient imminently dying and requiring palliative sedation?

   • YES → May need to increase doses or add additional agents 1